Publications

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy vs placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial

Researchers conducted this randomised, double-blind, placebo-controlled, phase 2 trial to test the safety and effectiveness of adjuvant nivolumab plus ipilimumab or nivolumab monotherapy vs a placebo in patients with stage IV melanoma with no evidence of disease.

Read More
MRV News
Melanoma News
Archive
Menu